Skip to main content

Dealmaking for Life Sciences Issuers in the COVID-19 World

May
12
2020

Date: May 12, 2020

Time: 1:00PM - 2:00PM

Location: View the Webinar Recording

The COVID-19 global pandemic has fundamentally altered how equity financing and M&A transactions are being structured by and for life sciences issuers.

Join this panel of life sciences industry experts, from investment bankers and advisers to equity capital market participants and companies exploring M&A transactions, to learn about what trends and opportunities they see as the “new normal” continues to evolve.

Speakers

Professional Cropped Gates Megan Mintz

Megan N. Gates

Moderator

Megan N. Gates is a Mintz corporate and securities attorney who guides public companies through capital-raising transactions, SEC reporting obligations, and mergers and acquisitions. She advises clients on corporate governance and SEC compliance matters in the life sciences and other industries.
Professional Cropped Rudy John Mintz

John T. Rudy

Panelist

John T. Rudy is a Mintz Member who represents clients in capital markets transactions, securities, equity debt financings, and mergers and acquisitions. John's clients include public and private companies and investment banks. Before joining Mintz, he was an associate in a New York law firm.
Professional Cropped Mantell Marc Mintz

Marc D. Mantell

Panelist

Marc D. Mantell handles corporate and securities law matters at Mintz, primarily for technology clients. He represents companies, investors, underwriters, and other parties in mergers and acquisitions, securities offerings, debt financings, and other transactions.
Helen Cheng

Helen Cheng

Panelist

Managing Director, Houlihan Lokey
Ben Conway

Ben Conway

Panelist

Managing Director, Consilium Partners
Eugene Rozelman

Eugene Rozelman

Panelist

Managing Director, Head of Biotechnology & Specialty Pharmaceuticals (US), Canaccord Genuity